Myeloperoxidase, a risk indicator for cardiovascular disease

CAFC
  • US 9,164,095 B2
  • Filed: 12/20/2005
  • Issued: 10/20/2015
  • Est. Priority Date: 01/02/2001
  • Status: Active Grant
First Claim
Patent Images

1. A method for administering a lipid lowering agent to a human patient based on elevated levels of protein-bound nitrotyrosine, comprising:

  • (a) performing an enzyme linked immunosorbent assay (ELISA) comprising contacting a bodily serum or plasma sample with a monoclonal anti-nitrotyrosine antibody;

    (b) selecting a patient whose nitrotyrosine levels are greater than a predetermined value from comparable samples from an apparently healthy control population; and

    (c) administering a lipid lowering agent to the selected human patient.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×